BrightSpring Health Services/$BTSG
1D1W1MYTD1Y5YMAX
Capital at risk
About BrightSpring Health Services
BrightSpring Health Services Inc is a home and community-based healthcare services platform, focused on delivering complementary pharmacy and provider services to complex patients. Its platform delivers clinical services and pharmacy solutions across Medicare, Medicaid, and commercially insured populations. Its segments include Pharmacy Solutions, Provider Services, and others. It generates the majority of its revenue from the Pharmacy Solutions segment.
- Ticker
- $BTSG
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Louisville, United States
- Website
- www.brightspringhealth.com
BTSG Metrics
BasicAdvanced
$12B
34.53
$1.64
1.85
-
Price and volume
Market cap
$12B
Beta
1.85
52-week high
$73.75
52-week low
$26.28
Average daily volume
2.5M
Financial strength
Current ratio
1.588
Quick ratio
1.086
Long term debt to equity
1.115
Total debt to equity
1.16
Interest coverage (TTM)
3.06%
Profitability
EBITDA (TTM)
626.818
Gross margin (TTM)
12.38%
Net profit margin (TTM)
2.55%
Operating margin (TTM)
3.24%
Effective tax rate (TTM)
16.11%
Management effectiveness
Return on assets (TTM)
4.88%
Return on equity (TTM)
13.04%
Valuation
Price to earnings (TTM)
34.526
Price to revenue (TTM)
0.807
Price to book
5.69
Price to tangible book (TTM)
-11.65
Price to free cash flow (TTM)
28.812
Free cash flow yield (TTM)
3.47%
Free cash flow per share (TTM)
1.963
Growth
Revenue change (TTM)
26.35%
Earnings per share change (TTM)
399.96%
3-year revenue growth (CAGR)
20.83%
3-year earnings per share growth (CAGR)
25.87%
What the Analysts think about BTSG
Analyst ratings (Buy, Hold, Sell) for BrightSpring Health Services stock.
Analyst projections of the future price of BrightSpring Health Services stock.
Bulls say / Bears say
Q2 revenue rose 23% year over year to $3.87 billion and Adjusted EBITDA increased 44% to $206 million, prompting management to raise 2026 guidance to $15.1-$15.425 billion of revenue and $820-$845 million of Adjusted EBITDA. (BrightSpring Health Services)
Provider Services revenue grew 30% in Q2, with home-health average daily census up 54%, while Pharmacy Solutions revenue rose 22%; this supports the thesis that the platform can grow beyond its legacy community-living operations. (BrightSpring Health Services)
BrightSpring used divestiture proceeds to repay $300 million of first-lien debt and refinance the remainder at a lower spread, reducing leverage to 2.15x at June 30 from 2.27x at March 31 and lowering future interest expense. (BrightSpring Health Services)
Pharmacy Solutions represented approximately 88% of Q2 revenue, while prescriptions dispensed fell 1% year over year for the first half; continued growth therefore depends heavily on higher revenue per prescription and favorable specialty-drug mix. (SEC)
BrightSpring reported an 8% decline in Home and Community Pharmacy revenue, citing Inflation Reduction Act effects including Medicare drug-price negotiations, rebates, and statutory price caps; further reimbursement changes could pressure growth and margins. (SEC)
Despite deleveraging, BrightSpring had $2.25 billion of total debt at June 30, 2026, largely at variable rates, and remains subject to restrictive credit-agreement covenants; higher rates or weaker EBITDA could constrain acquisitions and equity returns. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 10 Sept 2026.
BTSG Financial Performance
Revenues and expenses
BTSG Earnings Performance
Company profitability
Upcoming events
No upcoming events
BTSG News
AllArticlesVideos
Funds containing BTSG
AllEURUSDGBP
Fund name | Fund size | $BTSG weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.31% |
SPDR S&P 400 US Mid Cap$SPY4 | $6.3B | 0.28% |
SPDR S&P 400 US Mid Cap£SPX4 | £4.7B | 0.28% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.09% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.09% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.